Clinical Trials · NCT05459844
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Sinotau Pharmaceutical Group
- Enrollment
- 196
- Start date
- Aug 2022
- Locations
- 23 sites, China
- Primary endpoint
- Progression Free Survival (PFS) assessed by BIRC